FAQ/Help |
Calendar |
Search |
Today's Posts |
12-31-2011, 11:04 AM | #1 | ||
|
|||
Magnate
|
|
||
Reply With Quote |
01-01-2012, 05:32 PM | #2 | |||
|
||||
Member
|
Thanks for the encouraging article.
1) taking out the garbage (from cell function) 2) protecting and beefing up the mitochondria and 3) inosine trials to increase urate levels http://www.medicalnewstoday.com/releases/104075.php Does anyone know the status of this study funded by MJFF -phase two began in '08. Are these our bets bets at the current time? Quote:
__________________
VictoriaLou . |
|||
Reply With Quote |
01-02-2012, 12:47 PM | #3 | ||
|
|||
Magnate
|
not sure as far as prevention/slowing progression, watching ceregene's gene therapy, oxford bioscience. neurologix phase3 dependent on finding funding, company pretty shaky.
newest drug is reformulated sinemet http://finance.yahoo.com/news/Impax-...61589.html?x=0 |
||
Reply With Quote |
"Thanks for this!" says: | VICTORIALOU (01-02-2012) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Parkinson's Disease: Why Dopamine Replacement Therapy Effect On Cognition | Parkinson's Disease | |||
MDS 2009: Creativity Linked to Dopamine Agonists in Parkinson's Disease | Parkinson's Disease | |||
Dopamine transporter relation to dopamine turnover in Parkinson's disease | Parkinson's Disease |